Drugmakers face 100% tariff unless they cut prices or produce drugs in US - Reuters

The Trump administration is threatening pharmaceutical companies with a 100% tariff on imported drugs unless they either reduce prices or shift manufacturing to the United States. The ultimatum represents an aggressive attempt to leverage tariff policy to reshape the domestic drug market and address what the White House views as inflated medication costs. Drugmakers currently rely heavily on imported active pharmaceutical ingredients and finished products, making them vulnerable to such levies. The policy could force major pricing negotiations or significant capital investment in U.S. production facilities, fundamentally altering industry economics. The move signals the administration's willingness to use tariffs across multiple sectors to achieve domestic policy objectives beyond traditional trade concerns.